The researchers plan to create a biological drug that would enter the body via a stent to seek lesions and treat coronary blockages to prevent heart failure. If successful, the drug would be the first of its kind to function in congruence with the biochemical activity that causes an adverse event.
“All available medicines treat only symptoms to slow the onset of heart failure. The design of our biologics improves current methods of controlled release, because it takes advantage of specific biochemical events that occur during heart failure,” Josh Sakon, PhD, leader of the experimental study, said in a news release.
The study is funded by two $30,000 grants from the National Institutes of Health and the University of Arkansas Chancellor’s Fund.
More articles on pharmacy:
Georgia pharma company recalls thyroid drug for super potency
CVS to deliver prescriptions via self-driving cars
Novartis to produce experimental COVID-19 vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
